How Yasmin works

Yasmin is a small-dose monophasic electrical contraceptive and a short-acting contraceptive. One tablet contains 0.03 mg of ethynyl estradiol and 3 mg of drospirenone, which can achieve nearly 100% contraceptive effectiveness and provide excellent cycle time control. What is the actual effect of Yasmin emergency contraception and its contraceptive principle?

The contraceptive efficacy of contraceptive pills (COCs) is based on the interaction of many factors, the most important of which are the inhibition of ovulation and changes in cervical secretion. In addition to the contraceptive efficacy, COCs, although they have the negative features mentioned in (warnings and side effects), also have many beneficial features: such as more regular menstrual cycles, relief of menstrual pain, and less bleeding. The latter can reduce the occurrence of zinc deficiency.

Drospirenone Yasmin has other beneficial properties in addition to its contraceptive properties. Drospirenone has anti-salvocorticoid properties, which can prevent weight gain and other symptoms caused by fluid retention. It resists estrogen-related sodium retention, provides good tolerability, and has a positive active effect on premenstrual syndrome (PMS). In combination with ethinyl estradiol, drospirenone increases high-density lipoprotein (HDL) levels and shows a good lipid profile.

The anti-androgenic properties of drospirenone have a beneficial effect on the skin, reducing acne damage and sebaceous gland formation. In addition, drospirenone does not resist the increase in SHBG associated with ethinyl estradiol, which is beneficial for binding to endogenous androgens and degrading them.

Drospirenone does not have any androgen, estrogen, hormonal, or anti-hormonal specificity. This feature, combined with its anti-salting and anti-androgenic properties, makes the biochemical and pharmacological properties of drospirenone very similar to those of pure natural estrogen.

In addition, there is direct evidence that the risk of endometrial and ovarian cancer is reduced. Furthermore, higher doses of COCs (ethinylestradiol 0.05 mg) have been shown to reduce the incidence of ovarian cysts, pelvic inflammatory disease, mild breast disease, and ectopic pregnancy. Whether this also applies to lower doses of COCs remains to be confirmed.